LONDON (Reuters) -Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections. The company declined to comment on the timeline. “Globally (human insulin pens) will be phased out over time and human insulin will be available …
